A Post Marketing Surveillance Study Assessing the Long-term Efficacy and Safety of Aptivus Co-administered With Low-dose Ritonavir in Treatment Experienced Patients With HIV-1 Infection in the Daily Clinical Practice.

Boehringer Ingelheim

Status: Completed

Conditions: HIV Infections

Treatments: Drug: Tipranavir; Drug: ritonavir

Study type: Observational

Funder types: Industry

Identifiers

NCT00976950

1182.147

Details and patient eligibility

About

The aim of this trial is to evaluate the safety and virological and immunological efficacy of Aptivus in treatment-experienced patients with advanced HIV-1 infection who had developed resistance to more than one protease inhibitor.

Enrollment: 42 patients

Sex: All

Ages: 18+ years old

Volunteers: No Healthy Volunteers

Inclusion criteria

1. HIV-1 infected patients who are treatment experienced and infected with HIV-1 strains resistant to more than one protease inhibitor and no other therapeutic options.
2. The inclusion criteria follow the same criteria which are describe in the newest SPC

Exclusion criteria

The exclusion criteria follow the same criteria which are describe in the newest SPC

Trial design

42 participants in 1 patient group

Patients with HIV-1 infection

Treatment:

Drug: Tipranavir

Drug: ritonavir